Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Weird. I have no issues opening. I read one of the articles last night on Christie's committee missing their 2nd deadline in putting together plan for opiates.
That is my favorite gauge. Lol
That I agree. The breakdown of ELTP is not from shorting, but rather lack of fundamentals & increased uncertainty. Investors hate crappy results, but they hate uncertainty even more. Much tougher to model out.
You can short penny stocks through Interactive Brokers and any other broker not based in US. In addition, you just need to understand the legal & tax implications for doing so as a US citizen.
10% is much more valuable, but it is just relative. He is leading all down a path of "hope".
Let me ask you this. Why do you think an Adcom was passed up to discuss labeling? SequestOx issues go well beyond the labeling.
Except for the fact that the CEO stated "we were hoping for better results" and stopped all studies and further pursuit of the program. Flopping like a dead fish out of water.
Significant upside in company does not exist on generics alone. IR was needed.
Going back to Carter's baseball analogy - the company will only have ability for a base hit every now and then. No doubles, triples, home runs or grand slams. There has been more fouling out and screaming touchdown as Elite aims to have any of their tech approved.
Remember how confident Nasrat was about SequestOx with all the studies proving the tech? Well, reality bites. Platform means squat without FDA's approval on at least an ER ADT.
That was a dead cat bounce.
But wait!! Revenues are "rising"! LOL
All prior CT's that have expired have been worthless info.
The real reason for the CT is to hide the number of jelly beans in the jar on Carter's desk. He counts them every morning since there are no revenue dollars to count.
And how long does it normally take for the ER ADT's to be approved? How about the most recent? It is well beyond 10-12 months.
Or rather this is what happens when he sells his shares, he hides for a bit.
No, nothing to do with Dr Reddy
Not fraud. Just continuation of a lack of attention to small details...like the minor Tmax issue. No worries though. Nothing will stop SequestOx. Not even poor results or the FDA. Santa Hakim is here to make things all better and leave a big turd in your stocking.
So is heroin on the street corner except it is probably sold with a better margin then Elite can capture.
Very much akin to my children entering the multi multi billion beverage industry with their lemonade stand. Look at the IMS market we are in! Wow!
I think they have a Trimipramine competitor. There goes our profit.
Haha! That made my day.
Thanks for the update. This is news to me.
Wait, how many times was it mentioned that Puracap is our preferred partner since they own the Chinese opiate market. Strategy here is just like at Elite - being blown like dust in the wind and the flip-flopping of politicians. Today's news is a nonevent.
This is probably a simple amendment excluding immediate release tech & giving SunGen more of the profits since Elite's tech still has yet to be approved by FDA. LOL
For what? There was no visible change. Notice the IMS is the exact same that has been quoted many times. Using IMS data is a joke - you need to know the market potential for their product alone. It isn't IMS for sure. Just normal bloated speak.
Since IR tech failed, management needs to show something, but nothing was new here other than a little more insight into the market segments. Hilarious.
Now think about this - why would the FDA have Elite go through all the rigamarole that they have since late 2015 since the CRL (article misstated year) if all this was a labeling issue? Elite didn't even get an Adcom to discuss labeling. That ship has sailed.
Then you need to learn to read financials. Revenue has consistently decreased over the last several quarters.
Only if ER fails with an approval will that be the case.
Neither is any decent FDA approval...unless you are counting Trimipramine. LOLOLOL
If ER doesn't get approved this will go to 0.02 for sure. Who knows what else management is hiding after Tmax surprise.
Very true. Sadly, much of that historic speculation has turned out to be true of SequestOx and management's capability.
Crazy to think that SequestOx being an IR candidate had Tmax that falls into the normal realm of ER. Hmmmm....
No.
No.
And No.
Anything else is speculation.
Hmmm...makes zero sense why they would want big hero Elite to continue with the study. My guess is there is much more to the tech that we haven't seen raising eyebrows.
"Nothing will stop us" says the CEO...except for the FDA & their own trial results, of course.
Claw backs are extremely rare on comp. In the US, boards have the mentality of "I'll scratch your back if you scratch mine." Nothing will come out of this.
C'mon Lasers. Why would Elite make any additional data public? They have provided minimal data to say the least and have cherry picked certain highlights for PRs.
They hire out professionals to perform the statistical analysis. Granular details on the study is not going to be made public. "Not gonna do it."
I like the clarification of the ANDA filing, the same "this quarter" wording was used as it was during the time of the conference call that fell during the prior quarter. He just bought himself 3 more months.
Perhaps it should be rephrased as questions for wannabe amateur management.
Not clear = fail
You clearly don't understand what results the company was seeking. Here is a big hint:
Why is the company stopping the pursuit of SequestOx? They have much greater insights than we do. You don't stop a program if it met the primary endpoints. The reformulation caused even more issues than the original. This is plain as day.
Even then, the results didn't meet the primary endpoint. They were worse than expected. Path forward is shut down.
But the Tmax was high on the original formulation. You don't want similar. You want better. It is clearly not what the results show.